CoChat
Sign Up
Cited by 31

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Global Phosphoproteomic Profiling Reveals Distinct Signatures in B-Cell Non-Hodgkin Lymphomas

Rolland, Delphine, Basrur, Venkatesha, Conlon, Kevin, Wolfe, Thomas, Fermin, Damian, Nesvizhskii, Alexey I., Lim, Megan S., Elenitoba-Johnson, Kojo S.J.·2014·The American Journal of Pathology
DOI 10.1016/j.ajpath.2014.01.036
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2014.01.036

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Phosphorylation at corresponding sites in SNX1, SNX3, SNX12, and SNX17 has been reported in various cancer types.

    “phosphorylation at corresponding sites in SNX1, SNX3, SNX12, and SNX17 has been reported in various cancer types (47, 48, 49, 50, 51, 52)”

    From Phosphorylation of SNX17 impedes activation of Retriever-mediated sorting (2025) · cites this paper as [52]

    The Identification and Quantification and Discussion passages report phosphorylation in B-cell non-Hodgkin lymphomas, but do not identify phosphorylation sites in SNX1, SNX3, SNX12, or SNX17. Searches for those proteins and for “sorting nexin” found no passage addressing the claimed sites or their occurrence across cancer types. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. Hunter, 2000, Signaling–2000 and beyond, Cell, 100, 113, 10.1016/S0092-8674(00)81688-8 · DOI · Paper page
  2. Schlessinger, 2000, Cell signaling by receptor tyrosine kinases, Cell, 103, 211, 10.1016/S0092-8674(00)00114-8 · DOI · Paper page
  3. Blume-Jensen, 2001, Oncogenic kinase signalling, Nature, 411, 355, 10.1038/35077225 · DOI · Paper page
  4. Harsha, 2010, Phosphoproteomics in cancer, Mol Oncol, 4, 482, 10.1016/j.molonc.2010.09.004 · DOI
  5. Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867 · DOI
  6. Blanke, 2008, Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033, J Clin Oncol, 26, 626, 10.1200/JCO.2007.13.4452 · DOI
  7. Lenz, 2008, Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proc Natl Acad Sci U S A, 105, 13520, 10.1073/pnas.0804295105 · DOI
  8. De Paepe, 2003, ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma, Blood, 102, 2638, 10.1182/blood-2003-04-1050 · DOI
  9. Rosenwald, 2001, Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia, J Exp Med, 194, 1639, 10.1084/jem.194.11.1639 · DOI
  10. Macek, 2009, Global and site-specific quantitative phosphoproteomics: principles and applications, Annu Rev Pharmacol Toxicol, 49, 199, 10.1146/annurev.pharmtox.011008.145606 · DOI
  11. Larsen, 2005, Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns, Mol Cell Proteomics, 4, 873, 10.1074/mcp.T500007-MCP200 · DOI
  12. Rush, 2005, Immunoaffinity profiling of tyrosine phosphorylation in cancer cells, Nat Biotechnol, 23, 94, 10.1038/nbt1046 · DOI
  13. Rikova, 2007, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 131, 1190, 10.1016/j.cell.2007.11.025 · DOI · Paper page
  14. Kessner, 2008, ProteoWizard: open source software for rapid proteomics tools development, Bioinformatics, 24, 2534, 10.1093/bioinformatics/btn323 · DOI · Paper page
  15. Fenyo, 2003, A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes, Anal Chem, 75, 768, 10.1021/ac0258709 · DOI
  16. MacLean, 2006, General framework for developing and evaluating database scoring algorithms using the TANDEM search engine, Bioinformatics, 22, 2830, 10.1093/bioinformatics/btl379 · DOI
  17. Keller, 2002, Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search, Anal Chem, 74, 5383, 10.1021/ac025747h · DOI
  18. Nesvizhskii, 2003, A statistical model for identifying proteins by tandem mass spectrometry, Anal Chem, 75, 4646, 10.1021/ac0341261 · DOI
  19. Pedrioli, 2010, Trans-proteomic pipeline: a pipeline for proteomic analysis, Methods Mol Biol, 604, 213, 10.1007/978-1-60761-444-9_15 · DOI
  20. Fermin, 2011, Abacus: a computational tool for extracting and pre-processing spectral count data for label-free quantitative proteomic analysis, Proteomics, 11, 1340, 10.1002/pmic.201000650 · DOI
  21. Schwartz, 2009, Predicting protein post-translational modifications using meta-analysis of proteome scale data sets, Mol Cell Proteomics, 8, 365, 10.1074/mcp.M800332-MCP200 · DOI
  22. Suzuki, 2006, Pvclust: an R package for assessing the uncertainty in hierarchical clustering, Bioinformatics, 22, 1540, 10.1093/bioinformatics/btl117 · DOI
  23. Vizcaino, 2013, The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013, Nucleic Acids Res, 41, D1063, 10.1093/nar/gks1262 · DOI · Paper page
  24. Kim, 2012, Wnt5a is secreted by follicular dendritic cells to protect germinal center B cells via Wnt/Ca2+/NFAT/NF-kappaB-B cell lymphoma 6 signaling, J Immunol, 188, 182, 10.4049/jimmunol.1102297 · DOI
  25. Wilker, 2008, Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation, Nat Immunol, 9, 603, 10.1038/ni.1609 · DOI
  26. Bracken, 2008, Regulation of cyclin D1 RNA stability by SNIP1, Cancer Res, 68, 7621, 10.1158/0008-5472.CAN-08-1217 · DOI
  27. Bruno, 2002, Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb, Cancer Cell, 2, 387, 10.1016/S1535-6108(02)00182-4 · DOI
  28. Szklarczyk, 2011, The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored, Nucleic Acids Res, 39, D561, 10.1093/nar/gkq973 · DOI
  29. Huang da, 2009, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nat Protoc, 4, 44, 10.1038/nprot.2008.211 · DOI · Paper page
  30. Huang da, 2009, Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists, Nucleic Acids Res, 37, 1, 10.1093/nar/gkn923 · DOI · Paper page
  31. Takeuchi, 2000, Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk, J Biol Chem, 275, 29183, 10.1074/jbc.C000326200 · DOI
  32. Brdicka, 2000, Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation, J Exp Med, 191, 1591, 10.1084/jem.191.9.1591 · DOI
  33. Casado, 2013, Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors, Genome Biol, 14, R37, 10.1186/gb-2013-14-4-r37 · DOI
  34. LeBien, 2008, B lymphocytes: how they develop and function, Blood, 112, 1570, 10.1182/blood-2008-02-078071 · DOI
  35. Kuppers, 2005, Mechanisms of B-cell lymphoma pathogenesis, Nat Rev Cancer, 5, 251, 10.1038/nrc1589 · DOI
  36. Wiestner, 2007, Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival, Blood, 109, 4599, 10.1182/blood-2006-08-039859 · DOI
  37. Camps, 2006, Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines, Leuk Res, 30, 923, 10.1016/j.leukres.2005.11.013 · DOI
  38. M’Kacher, 2003, Blastoid mantle cell lymphoma: evidence for nonrandom cytogenetic abnormalities additional to t(11;14) and generation of a mouse model, Cancer Genet Cytogenet, 143, 32, 10.1016/S0165-4608(02)00823-3 · DOI
  39. Davis, 2010, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, 463, 88, 10.1038/nature08638 · DOI
  40. Honigberg, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci U S A, 107, 13075, 10.1073/pnas.1004594107 · DOI · Paper page
  41. Flemming, 2010, Target discovery: blocking BTK in B-cell disorders, Nat Rev Drug Discov, 9, 681, 10.1038/nrd3262 · DOI
  42. Cheng, 2011, SYK inhibition and response prediction in diffuse large B-cell lymphoma, Blood, 118, 6342, 10.1182/blood-2011-02-333773 · DOI
  43. Kanou, 2011, The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation, Mol Cancer Res, 9, 103, 10.1158/1541-7786.MCR-10-0340 · DOI
  44. Sirvent, 2010, Src family tyrosine kinases: driven colon cancer cell invasion is induced by Csk membrane delocalization, Oncogene, 29, 1303, 10.1038/onc.2009.450 · DOI · Paper page
  45. Janssen, 2003, Adaptor proteins in lymphocyte activation, Curr Opin Immunol, 15, 269, 10.1016/S0952-7915(03)00044-X · DOI
  46. Smida, 2007, A novel negative regulatory function of the phosphoprotein associated with glycosphingolipid-enriched microdomains: blocking Ras activation, Blood, 110, 596, 10.1182/blood-2006-07-038752 · DOI
  47. Kawabuchi, 2000, Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases, Nature, 404, 999, 10.1038/35010121 · DOI
  48. Svec, 2005, Expression pattern of adaptor protein PAG: correlation between secondary lymphatic follicle and histogenetically related malignant lymphomas, Immunol Lett, 100, 94, 10.1016/j.imlet.2005.05.002 · DOI
  49. Svec, 2007, Expression of transmembrane adaptor protein PAG/Cbp in diffuse large B-cell lymphoma: immunohistochemical study of 73 cases, Pathol Res Pract, 203, 193, 10.1016/j.prp.2007.01.005 · DOI
  50. Solheim, 2008, Interactions between the Fyn SH3-domain and adaptor protein Cbp/PAG derived ligands, effects on kinase activity and affinity, FEBS J, 275, 4863, 10.1111/j.1742-4658.2008.06626.x · DOI

Cited by

Sorted by citations

Metadata

Authors
Rolland, D., Basrur, V., Conlon, K., Wolfe, T., Fermin, D., Nesvizhskii, A. I., Lim, M. S., & Elenitoba-Johnson, K. S. J.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2014-05
Volume
184
Issue
5
Pages
1331-1342
ISSN
0002-9440
DOI
10.1016/j.ajpath.2014.01.036
Cited by
31
References
4
Language
en
Licence
Funders
  • National Institutes of Health (R01 CA136905, R01 CA140806, R01-CA126239, R01-GM094231, R01 DE119249)
  • Fondation pour la Recherche Médicale (SPE20091117389)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review